Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Forsteo ® (teriparatid)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Relevant Information from Summary of Product Characteristics
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).1
Forsteo is contraindicated in patients with prior external beam or implant radiation therapy to the skeleton.1
Clinical Trial Experience
Patients with a history of carcinoma in the previous five years or with a current suspicion were excluded from participating in clinical trials with teriparatide. However, patients with excised superficial lesions of the skin and those with a history of carcinoma in situ of the cervix or uterus were allowed to participate.2
There was no apparent increase in the incidence of cancers among all study participants treated with teriparatide compared with placebo during clinical trials.2
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Datum fӧr senaste ӧversyn 2020 M03 03